Utilization of exosome-based therapies to augment anti-PD-1/PD-L1 therapies
Abstract
The development of immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway has significantly transformed the landscape of cancer treatment. However, resistance mechanisms such a…